alkylamino
diazachrysenebas
small
molecul
previous
identifi
inhibitor
botulinum
neurotoxin
serotyp
light
chain
metalloproteas
subsequ
varieti
deriv
chemotyp
synthes
develop
structureact
relationship
inhibitor
bonta
lc
threedimension
analys
indic
half
origin
discov
structur
superimpos
well
antimalari
agent
observ
led
discoveri
sever
deriv
potent
vitro
inhibitor
plasmodium
falciparum
gener
efficaci
cqresist
strain
cqsuscept
strain
addit
inhibit
format
efficaci
antimalari
employ
mechan
action
analog
antimalari
well
toler
normal
cell
one
candid
also
effect
administ
oral
rodentbas
malaria
model
final
deriv
examin
ebola
filoviru
inhibit
assay
employ
cell
three
provid
promis
antivir
activ
accept
low
toxic
present
manuscript
describ
seri
aminoalkyl
diazachrysen
base
deriv
inhibit
three
differ
pathogen
target
botulinum
neurotoxin
serotyp
light
chain
bonta
lc
zn
ii
metalloproteas
respons
paralysi
associ
botul
plasmodium
falciparum
caus
malaria
ebola
filoviru
caus
hemorrhag
fever
three
target
describ
botulinum
neurotoxin
bont
secret
anaerob
sporeform
bacterium
clostridium
botulinum
potent
bacteri
toxin
due
eas
dissemin
lethal
bont
classifi
categori
highest
prioriti
biothreat
agent
center
diseas
control
prevent
cdc
seven
known
bont
serotyp
design
ag
compos
heavi
chain
hc
compon
light
chain
lc
compon
lc
zn
ii
metalloproteas
hc
mediat
transloc
neuron
cytosol
cell
intern
lc
liber
hc
depend
serotyp
cleav
one
three
protein
signific
interest
includ
hematin
bind
drug
revers
acridon
hybrid
new
acridin
deriv
ebola
filoviru
ebov
member
famili
filovirida
order
mononegaviral
genet
ebov
nonseg
singlestrand
neg
sens
rna
viru
endem
subsaharan
africa
sporad
outbreak
natur
occur
ebov
zair
zair
viru
report
caus
sever
hemorrhag
fever
lethal
rate
approach
major
concern
regard
viru
includ
potenti
global
spread
due
increas
intern
travel
possibl
use
biolog
weapon
therefor
like
bont
pathogen
list
cdc
categori
biothreat
agent
approv
therapeut
option
avail
prophylaxi
andor
treatment
infect
individu
current
medic
respons
outbreak
reli
systemat
case
identif
contact
trace
strategi
immedi
isol
suspect
case
special
isol
ward
therefor
vaccin
well
new
antifiloviru
drug
need
counter
pathogen
howev
review
literatur
afford
hand
small
molecul
act
ebov
inhibitor
herein
provid
result
indic
deriv
singl
chemotyp
ie
small
molecul
possess
abil
inhibit
three
unrel
pathogen
describ
bacteri
toxin
bonta
lc
protozoan
malaria
filoviru
ebov
respect
import
discov
small
molecul
employ
differ
mechan
action
treat
one
targetpathogen
paradigm
costeffect
mean
treat
diseas
gener
especi
affect
would
affect
small
popul
well
popul
third
world
countri
eg
malaria
one
exampl
small
molecul
miltefosin
origin
develop
treat
breast
cancer
later
found
effect
treatment
viscer
leishmaniasi
sandfli
transmit
parasit
diseas
estim
kill
peopl
year
second
exampl
adefovir
dipivoxil
drug
use
treat
chronic
hepat
b
viru
infect
subsequ
identifi
competit
inhibitor
anthrax
edema
factor
key
virul
factor
anthrax
pathogenesi
result
discuss
initi
discov
novel
small
molecul
nonpeptid
inhibitor
smnpi
bonta
lc
highthroughput
screen
small
molecul
librari
conduct
hit
screen
verifi
use
previous
report
hplcbase
assay
chemic
divers
initi
discov
smnpi
rang
rigid
natur
product
michellamin
b
flexibl
bi
antimalari
agent
follow
threedimension
superimposit
share
smnpi
chemic
steric
featur
led
gener
common
pharmacophor
bonta
lc
inhibit
subsequ
studi
pharmacophor
provid
basi
develop
search
queri
use
databas
mine
potent
smnpi
interestingli
two
new
smnpi
chemotyp
discov
includ
acid
hybrid
hybrid
addit
smnpi
scheme
also
databas
journal
medicin
chemistri
articl
mine
nci
open
repositori
follow
use
unit
differ
smnpi
chemotyp
refin
pharmacophor
signific
research
report
herein
superimposit
smnpi
use
develop
refin
pharmacophor
model
indic
previous
identifi
smnpi
also
antimalari
agent
partial
superimpos
remark
good
chemic
steric
complementar
figur
surprisingli
superimpos
antimalari
drug
cq
also
previous
found
weakli
inhibit
bonta
lc
complementari
chemic
steric
converg
observ
structur
converg
even
pronounc
two
condens
cq
molecul
superimpos
figur
observ
led
hypothesi
deriv
might
possess
antimalari
activ
initi
vitro
screen
p
falciparum
reveal
compound
activ
parasit
addit
toxic
pharmacokinet
profil
follow
vivo
test
one
potent
deriv
also
demonstr
signific
potenti
develop
smnpi
antimalari
therapeut
vide
infra
final
previous
discov
scheme
possess
antiebov
efficaci
vivo
toxic
consequ
deriv
examin
antiebov
activ
cellbas
assay
discov
three
deriv
afford
good
cellular
protect
low
toxic
dose
concentr
henc
result
indic
deriv
repres
new
lead
therapeut
develop
three
differ
pathogen
target
synthesi
daacbas
deriv
prior
discoveri
smnpi
also
activ
p
falciparum
strain
well
ebov
filoviru
deriv
synthes
provid
sar
develop
chemotyp
potenti
therapeut
counter
bonta
poison
specif
deriv
explor
bi
alkylamino
sidechain
gener
scheme
scheme
brief
synopsi
synthet
method
use
obtain
deriv
display
see
experiment
section
detail
first
commerci
avail
use
prepar
intermedi
via
conradlimpah
reaction
follow
react
pocl
give
dichlorid
yield
nucleophil
substitut
varieti
diamin
follow
hcl
salt
format
provid
deriv
overal
yield
rang
inhibit
bonta
lc
tabl
display
inhibitori
efficaci
examin
vitro
concentr
employ
well
establish
hplcbase
assay
bonta
lc
inhibit
note
indic
deriv
gener
determin
effect
modifi
bi
alkylamino
sidechain
ie
symmetr
moieti
extend
diazachrysen
core
scheme
bonta
lc
inhibitori
efficaci
overal
sar
indic
propylamino
linker
well
butylamino
linker
provid
slightli
increas
inhibitori
efficaci
versu
correspond
deriv
possess
ethyl
linker
tabl
specif
consist
potent
correspond
deriv
respect
tabl
contrast
differ
substitut
side
chain
termin
nitrogen
demonstr
consist
respect
bonta
lc
inhibit
exampl
primari
amin
deriv
slightli
potent
possess
n
ndimethyl
n
ndiethyl
substitu
respect
incorpor
side
chain
nitrogen
piperidin
morpholin
ring
respect
howev
incorpor
side
chain
nitrogen
pyrrolidin
ring
equipot
potent
well
deriv
present
tabl
result
indic
potenti
steric
limit
side
chain
amino
substitut
within
confin
bind
site
final
notabl
inhibit
data
indic
incorpor
termin
morpholin
ring
tabl
pronounc
neg
impact
inhibitori
efficaci
versu
present
deriv
data
appear
indic
either
unfavor
hydrophobicpolar
polarpolar
contact
one
morpholin
ring
oxygen
enzym
residu
occur
bonta
lc
bind
site
agreement
hypothesi
inhibit
data
show
possess
hydrophob
carbon
atom
posit
oxygen
atom
morpholin
ring
potent
smnpi
determin
type
inhibit
kinet
employ
smnpi
k
valu
determin
deriv
pair
inhibit
kinet
mirror
inhibit
data
tabl
k
valu
smnpi
respect
data
indic
among
potent
nonzn
ii
chelat
smnpi
report
literatur
date
addit
plot
bonta
lc
inhibit
versu
increas
concentr
indic
smnpi
competit
inhibitor
see
support
inform
figur
consequ
basi
fact
conserv
modif
made
bisalkylamino
sidechain
follow
smnpi
also
competit
inhibitor
furthermor
basi
sar
rel
close
inhibitori
rang
major
deriv
addit
synthes
requir
explor
impact
pronounc
alkylamino
side
chain
substitut
antimalari
activ
inhibit
p
falciparum
strain
shown
figur
classic
antimalari
agent
cq
superimpos
well
figur
observ
led
hypothesi
smnpi
bonta
lc
tabl
might
inhibit
p
falciparum
employ
similar
mechan
action
postul
antimalari
agent
ie
inhibit
hemozoin
format
subsequ
screen
vitro
three
p
falciparum
strain
clone
sierra
iunc
isol
suscept
cq
cq
pyrimethamin
reduc
suscept
mefloquin
halofantrin
clone
indochina
isol
resist
chloroquin
cqr
pyrimethamin
suscept
mefloquin
multidrugresist
strain
deriv
thailand
mdr
tabl
gener
hypothesi
correct
major
smnpi
potent
antimalari
agent
inhibit
prolifer
cqr
mdr
cq
p
falciparum
strain
low
nanomolar
rang
efficaci
smnpi
possess
side
chain
contain
primari
amino
group
least
activ
deriv
tabl
contrast
inhibitori
efficaci
deriv
gradual
improv
increas
substitut
basic
side
chain
nitrogen
compar
versu
tabl
moreov
introduct
piperidin
moieti
increas
antimalari
activ
introduct
heteroatom
piperidin
ring
provid
morpholin
substitu
enhanc
activ
examin
p
falciparum
strain
tabl
overal
examin
deriv
nine
possess
pronounc
antimalari
activ
potent
antimalari
agent
possess
diethyl
piperidin
morpholin
substitu
tabl
import
note
low
ic
valu
unusu
nonperoxid
deriv
antimalari
nine
deriv
activ
nm
cqr
strain
gener
potent
p
falciparum
cqr
strain
cq
strain
ri
ri
art
tabl
also
emphas
potent
standard
antimalari
drug
cq
mfq
art
tabl
particular
ratio
increas
inhibitori
potenc
indic
smnpi
time
potent
cq
mfq
art
respect
time
potent
mfq
art
cq
respect
time
potent
art
mfq
cq
respect
tabl
obtain
basic
inform
antimalari
mechan
action
employ
smnpi
shown
tabl
deriv
screen
suppress
format
use
previous
describ
inhibitori
activ
assay
bhia
specif
assay
monitor
small
moleculebas
interfer
heme
detoxif
process
employ
p
falciparum
line
hypothesi
smnpi
like
antimalari
would
interfer
heme
detoxif
mechan
result
tabl
indic
display
dosedepend
inhibit
format
ic
valu
consider
lower
cq
thu
demonstr
significantli
better
abil
interact
hematin
cq
well
confirm
hypothesi
inform
dosedepend
inhibit
format
select
smnpi
see
support
inform
figur
analysi
toxic
investig
smnpi
base
scaffold
close
attent
paid
possibl
toxic
issu
first
bi
n
ndiethyl
substitut
deriv
bismorpholino
substitut
deriv
chosen
advanc
toxic
screen
due
potenc
cqr
strain
mdr
strain
ri
ri
ri
respect
tabl
brief
smnpi
cytotox
examin
rat
macrophag
cell
line
low
toxic
observ
three
deriv
ic
valu
rang
nm
tabl
moreov
potenc
smnpi
support
correspond
ic
valu
tabl
substanti
higher
standard
antimalari
drug
cq
mfq
art
anoth
import
characterist
lack
toxic
respect
high
antimalari
activ
three
p
falciparum
strain
particular
possess
high
select
indic
si
g
tabl
evid
vivo
clinic
toxic
note
p
berghei
pline
malariainfect
mice
outbr
icr
mice
mu
musculu
administ
dose
mgkg
bodi
weight
consecut
day
oral
rout
evidenc
lack
overt
physic
behavior
chang
treat
mice
moreov
sign
toxic
observ
note
twice
daili
observ
individu
mous
behavior
appear
routin
gross
necropsi
lesion
indic
death
due
fulmin
malaria
infect
addit
notabl
examin
nation
cancer
institut
panel
human
tumor
cell
line
start
concentr
inhibitori
activ
found
low
mean
growth
percent
respect
henc
data
indic
toxic
rang
cancer
cell
vitro
metabol
studi
also
perform
assess
bioavail
upon
oral
administr
metabol
stabil
assay
perform
use
mous
human
liver
microsom
mlm
hlm
respect
follow
result
indic
metabol
stabl
halfliv
min
mlm
hlm
bismorpholino
deriv
metabol
stabl
expos
mlm
min
appreci
stabl
expos
hlm
min
tabl
presum
low
toxic
observ
deriv
result
nsubstitut
posit
c
c
side
chain
may
suppress
metabol
activ
ultim
format
dna
adduct
regard
toxic
issu
need
investig
detail
nevertheless
initi
result
encourag
prompt
vivo
test
vivo
analysi
basi
favor
toxic
profil
indic
examin
antimalari
efficaci
mous
model
group
five
mice
employ
modifi
thompson
test
model
malaria
use
determin
blood
schizonticid
efficaci
model
icr
mice
infect
p
bergheiinfect
red
blood
cell
day
smnpi
administ
oral
mgkg
day
parasit
inocul
ie
postestablish
blood
stage
infect
establish
blood
stage
infect
confirm
posit
blood
smear
result
mice
studi
day
prior
smnpi
administr
smnpi
cure
one
mous
five
test
evidenc
neg
blood
smear
obtain
day
postinfect
four
mice
test
group
provid
blood
stage
suppress
activ
mice
succumb
infect
day
postparasit
inocul
contrast
control
mice
show
high
degre
parasitemia
succumb
infect
day
postparasit
inocul
presumpt
causal
prophylact
activ
also
investig
icr
mous
p
berghei
anka
strain
sporozoit
challeng
model
specif
mice
inocul
sporozoit
day
administ
day
investig
prophylact
potenti
day
smnpi
dose
one
hour
prior
sporozoit
inocul
result
studi
indic
provid
prophylact
protect
howev
delay
parasit
patenc
day
rel
control
mice
control
show
parasitemia
day
three
five
mice
oral
dose
mgkg
day
moreov
lower
prophylact
dose
mgkg
result
delay
patenc
day
one
five
mice
thompson
blood
stage
causal
prophylaxi
vivo
model
well
toler
produc
overt
clinic
manifest
toxic
note
twice
daili
observ
individu
mous
behavior
appear
routin
necropsi
conduct
mice
treat
result
clearli
show
mice
evalu
thompson
blood
stage
causal
prophylaxi
vivo
model
die
result
parasitemia
relat
toxic
evidenc
pale
emaci
carcass
presenc
darkgray
swollen
gross
lesion
liver
splenomegali
indic
malariainduc
death
sign
parasitemiainduc
death
also
observ
necroscopi
control
mice
importantli
toxic
observ
mice
treat
indic
twice
daili
observ
individu
mous
behavior
appear
routin
gross
necropsi
lesion
indic
mous
death
result
fulmin
malaria
infect
analysi
deriv
antiebov
activ
indic
introduct
previous
discov
counter
ebov
infect
vivo
moreov
public
found
broadspectrum
smnpi
inhibit
ebov
filoviru
also
genet
distinct
posit
negativestrand
rna
virus
includ
rift
valley
fever
bunyaviru
dengu
viru
flaviviru
hepat
c
viru
flaviviru
retroviru
thu
hypothes
antivir
activ
smnpi
result
modul
common
cellular
pathway
involv
viral
assembl
bud
util
wide
array
evolutionarili
distant
viru
famili
recent
find
prompt
examin
potenti
antiebov
activ
result
test
smnpi
cellbas
infect
assay
use
african
green
monkey
kidney
cell
indic
major
deriv
toxic
administ
concentr
howev
except
smnpi
provid
ebov
inhibit
respect
tabl
follow
doserespons
studi
conduct
indic
smnpi
possess
ic
valu
rang
tabl
cell
toxic
figur
henc
three
deriv
among
potent
ebov
inhibitor
discov
date
identif
smnpi
inhibitor
bonta
lc
result
synthes
varieti
deriv
provid
inhibit
enzym
furthermor
superimposit
origin
identifi
smnpi
compon
classic
antimalari
agent
indic
good
structur
chemic
complementar
prompt
investig
determin
deriv
describ
studi
might
also
inhibit
p
falciparum
malaria
addit
previou
studi
indic
inhibit
ebola
filoviru
therefor
deriv
also
examin
pathogen
henc
result
present
herein
provid
sar
chemotyp
examin
three
differ
pathogen
target
bacteri
toxin
bonta
lc
protozoan
p
falciparum
malaria
filoviru
ebov
result
studi
indic
present
smnpi
inhibit
three
unrel
pathogen
employ
three
differ
mechan
action
thu
demonstr
uniqu
antipathogen
potenti
chemotyp
specif
bonta
lc
metalloproteas
inhibit
achiev
via
interact
enzym
substrat
bind
cleft
antimalari
efficaci
appear
result
suppress
format
see
tabl
antiebov
efficaci
like
result
modul
host
cellular
pathway
exampl
pathway
facilit
viral
assembl
bud
interestingli
sar
inhibit
three
target
indic
gener
correl
deriv
side
chain
substitut
relat
inhibitori
potenc
across
pathogen
exampl
primari
amino
substitu
sidechain
core
result
increas
bonta
lc
inhibitori
potenc
incorpor
side
chain
basic
mm
mm
column
use
formic
acidacetonitril
mobil
phase
analys
preform
use
surveyor
separ
modul
coupl
thermofinnigan
tsq
tripl
quadrupol
mass
spectromet
mass
spectral
analys
done
use
electrospray
ioniz
posit
ion
mode
compound
analyz
puriti
hplc
use
water
hplc
dual
pump
system
equip
alltech
select
degass
system
dual
uvvi
detector
octadecylsilica
use
stationari
phase
symmetri
analyt
column
mm
mm
seri
eluent
made
follow
solvent
formic
acid
water
methanol
b
data
process
empow
softwar
use
compound
pure
detail
see
support
inform
diethyl
z
e
z
e
imino
suspens
g
mmol
commerci
sigmaaldrich
ethyl
acetoacet
ml
commerci
sigmaaldrich
ptsoh
g
mmol
anhyd
etoh
ml
heat
reflux
twoneck
roundbottom
flask
equip
deanstark
trap
fill
molecular
siev
heat
h
oil
bath
temp
stir
mixtur
cool
rt
evapor
dryness
crude
product
tritur
etoh
precipit
collect
uchner
funnel
dri
reduc
pressur
afford
g
lightbrown
powder
ir
atr
cm
mixtur
g
mmol
eaton
reagent
ml
mmol
commerci
sigmaaldrich
stir
h
reaction
mixtur
cool
ice
bath
care
pour
onto
satur
icecold
na
co
solut
g
na
co
ml
h
solid
filter
filtrat
wash
water
ml
etoh
ml
dri
reduc
pressur
afford
g
dion
lightbrown
powder
mp
ir
gener
procedur
synthesi
alkylamino
diazachrysen
tetrahydrochlorid
suspens
dichlorid
mg
mmol
correspond
amin
ml
stir
reflux
argon
h
mixtur
pour
onto
icecold
water
ml
solid
filter
wash
well
meoh
ml
dri
reduc
pressur
obtain
crude
base
suspend
meoh
ml
follow
addit
etohhcl
solut
ml
reaction
mixtur
vigor
stir
h
rt
solvent
remov
reduc
pressur
remain
solid
suspend
etoh
ml
filter
wash
well
articl
etoh
ml
et
ml
upon
dri
reduc
pressur
desir
product
obtain
n
n
bi
tetrahydrochlorid
dichlorid
mg
mmol
transform
use
gener
procedur
provid
correspond
amin
compound
yield
mg
mp
ir
kbr
tetrahydrochlorid
dichlorid
mg
mmol
transform
use
gener
procedur
provid
correspond
amin
n
dichlorid
mg
mmol
transform
use
gener
procedur
provid
correspond
amin
n
dichlorid
mg
mmol
transform
use
gener
procedur
provid
correspond
amin
n
ppm
n
bi
quino
tetrahydrochlorid
dichlorid
mg
mmol
transform
use
gener
procedur
provid
correspond
amin
perform
molecular
model
structur
cq
gener
use
builder
modul
follow
cq
energi
minim
employ
discov
modul
forcefield
distanc
depend
dielect
smnpi
steepest
descent
minim
perform
iter
follow
conjug
gradient
minim
norm
deriv
smnpi
manual
superimpos
achiev
optim
steric
atom
superimposit
ie
via
translat
rotat
bond
torsion
adjust
vitro
bonta
lc
metalloproteas
activ
determin
bonta
lc
percent
inhibit
smnpi
perform
previous
describ
assay
use
ntermin
acetyl
ctermin
amin
synthet
peptid
sequenc
residu
substrat
hydrolysi
determin
hplc
separ
product
substrat
follow
measur
peak
area
intrins
compound
fluoresc
quench
interfer
inhibit
measur
assay
mixtur
contain
mm
tween
ph
recombin
bonta
lc
peptid
substrat
mgml
bovin
serum
albumin
bsa
variou
smnpi
concentr
assay
run
quench
addit
tfa
analyz
use
reversephas
hplc
excess
zncl
ad
assay
ensur
smnpi
zn
ii
chelat
measur
percent
inhibit
perform
duplic
calcul
k
valu
determin
base
slope
dixon
plot
k
k
slope
v
max
substrat
conc
report
k
valu
averag
three
separ
experi
incorpor
nine
concentr
smnpi
vitro
antimalari
activ
vitro
antimalari
drug
suscept
screen
modif
procedur
first
publish
desjardin
et
al
briefli
bloodstag
model
group
five
mice
inocul
intraperiton
day
p
berghei
p
line
parasit
erythrocyt
obtain
infect
donor
mice
smnpi
suspend
tween
hect
administ
oral
daili
three
consecut
day
begin
day
postinfect
untreat
vehicl
control
mice
succumb
infect
day
postinfect
blood
smear
sampl
obtain
anim
determin
parasitemia
snip
tip
tail
thick
thin
blood
film
two
microscop
glass
slide
studi
day
postinfect
blood
smear
sampl
glass
slide
fix
methanol
stain
giemsa
stain
thick
film
determin
presenc
absenc
parasit
oilimmers
light
microscopi
object
examin
first
posit
thin
film
examin
detect
malaria
infect
erythrocyt
percent
parasitemia
count
total
erythrocyt
erythrocyt
erythrocyt
erythrocyt
mice
observ
twice
daili
clinic
sign
individu
weight
obtain
day
mice
human
euthan
show
moribund
condit
ie
unabl
move
two
blood
smear
obtain
prior
euthanasia
cure
defin
surviv
day
postsmnpi
treatment
evid
blood
parasit
without
evid
malaria
infect
upon
necropsi
ie
common
gross
necropsi
lesion
exoerythrocyt
model
infect
sporozoit
harvest
laboratoryrais
anophel
diru
mosquito
fed
donor
mice
infect
p
berghei
anka
strain
parasitemia
presenc
gametocyt
incub
mosquito
minimum
day
mosquito
salivari
gland
dissect
suspend
phosphat
buffer
salin
bsa
fresh
sporozoit
suspens
count
microscop
field
use
hemacytomet
phasecontrast
microscopi
determin
number
sporozoit
per
ml
mice
random
group
one
vehicl
control
group
experiment
group
requir
smnpi
suspend
tween
hect
day
day
within
h
prior
journal
medicin
chemistri
articl
inocul
day
mous
test
group
receiv
smnpi
determin
dose
plastic
oral
gavag
tube
control
anim
receiv
amount
vehicl
without
smnpi
day
mice
infect
standard
ml
dose
p
berghei
anka
strain
sporozoit
intraven
iv
inocul
anim
weight
obtain
studi
day
blood
smear
sampl
obtain
snip
tip
tail
thick
thin
blood
film
two
microscop
glass
slide
anim
studi
day
postinfect
determin
parasitemia
blood
smear
sampl
glass
slide
fix
methanol
stain
giemsa
stain
thick
film
presenc
absenc
parasit
oilimmers
light
microscopi
examin
first
posit
thin
film
examin
detect
malaria
infect
erythrocyt
percent
parasitemia
count
total
erythrocyt
erythrocyt
erythrocyt
erythrocyt
day
afterward
anim
parasitemia
exceed
euthan
mice
observ
twice
daili
clinic
sign
mortal
mortal
clinic
sign
record
day
clinic
sign
observ
two
blood
smear
obtain
parasitemia
detect
blood
smear
conduct
time
weekli
moribund
anim
show
combin
clinic
sign
within
earli
end
point
criteria
ie
unabl
move
sever
depress
reduc
appetit
extrem
pallor
ruffl
hair
euthan
employ
co
prior
euthanasia
two
blood
smear
obtain
parasitemia
determin
mice
surviv
day
euthan
co
mice
underw
necroscopi
smnpi
test
dose
consid
causal
prophylact
malari
infect
anim
test
group
develop
parasitemia
within
day
postinfect
blood
smear
result
remain
neg
throughout
day
experi
vitro
metabol
metabol
stabil
assay
sampl
prepar
perform
plate
format
use
tecan
genesi
robot
sampl
processor
follow
wrair
sop
sp
incub
carri
sodium
phosphat
buffer
ph
presenc
nadphregener
system
sodium
salt
mgcl
smnpi
microsom
mgml
total
protein
buffer
nadphregener
system
warm
reaction
initi
addit
dehydrogenas
sampl
quench
min
use
equal
volum
cold
acetonitril
sampl
centrifug
pellet
protein
supernat
analyz
lcmsm
use
fast
lc
gradient
method
deplet
parent
smnpi
signal
monitor
rel
signal
time
chromatogram
analyz
use
mass
spectrometri
softwar
xcalibur
quanbrows
calcul
smnpi
halfliv
firstord
rate
decay
assum
plot
natur
log
ln
compound
concentr
versu
time
gener
slope
line
k
halfliv
calcul
hepat
microsom
intrins
clearanc
calcul
use
formula
cl
int
vitro
ratemin
g
mgg
liver
cl
int
vitro
k
microsom
protein
content
per
gram
liver
microsom
protein
concentr
incub
buffer
vitro
toxic
assess
smnpi
toxic
raw
rat
macrophag
cell
line
macrophag
cell
line
raw
obtain
american
type
cultur
collect
cultur
previous
describ
step
experiment
procedur
perform
use
biomek
robot
plate
seed
cell
per
well
cultur
medium
approxim
h
start
assay
follow
morn
cell
expos
differ
smnpi
concentr
rang
incub
co
h
cell
viabil
assess
use
mtt
thiazolyl
blue
reduct
method
previous
describ
assay
plate
includ
background
target
dmso
control
experi
run
duplic
inhibitori
concentr
ic
determin
use
graphpad
prism
sigmoid
doserespons
variabl
slope
inhibitori
activ
assay
inhibit
format
smnpi
carri
use
inhibitori
activ
bhia
assay
full
detail
assay
publish
assay
perform
exactli
describ
indic
refer
antivir
studi
cell
cultur
employ
african
green
monkey
kidney
cell
atcc
grown
dulbecco
minim
essenti
medium
low
bicarbon
fetal
bovin
serum
mm
sodium
pyruv
non
essenti
amino
acid
recombin
zair
ebola
viru
ebov
engin
express
enhanc
gfp
ebovegfp
gene
kind
gift
dr
stuart
nichol
cdc
atlanta
gener
character
viru
describ
elsewher
ebovegfp
viru
propag
cell
viral
titer
determin
use
standard
plaqu
assay
detail
ebolaegfp
infect
assay
describ
elsewher
briefli
cell
cellswel
seed
bd
high
content
imag
plate
bd
bioscienc
allow
incub
overnight
primari
screen
smnpi
cell
pretreat
singl
concentr
h
infect
presenc
smnpi
ebovegfp
multipl
infect
moi
incub
h
co
cell
fix
formalin
day
wash
three
time
phosphat
buffer
salin
pb
cell
infect
ebolaegfp
stain
hc
cellmask
deep
red
cytoplasm
nuclear
stain
invitrogen
dilut
pb
nuclear
hoechst
dye
invitrogen
dilut
pb
doserespons
studi
smnpi
dilut
incub
cell
presenc
ebolaegfp
describ
elsewher
viral
infect
assay
autom
imag
acquisit
plate
perform
use
opera
confoc
reader
model
excit
high
sensit
qeh
perkinelm
waltham
imag
analyz
within
opera
environ
use
standard
acapella
script
associ
content
b
support
inform
plot
bonta
lc
inhibit
kinet
plot
dosedepend
inhibit
format
cq
vitro
cytotox
smnpi
versu
raw
mous
macrophag
cell
line
correspond
select
indic
antivir
inhibit
provid
select
smnpi
primari
screen
data
inhibit
smnpi
conc
analyt
data
combust
analys
p
hplc
analys
puriti
pp
synthesizedisol
smnpi
materi
avail
free
charg
via
internet
http
pubsacsorg
research
support
nato
public
diplomaci
divis
framework
scienc
peac
project
